Highly efficient selection of epitope specific antibody through competitive yeast display library sorting

References

• Dimitrov DS, Marks JD. Therapeutic antibodies: current state and future trends--is a paradigm change coming soon?. [xiii.] Methods Mol Biol 2009; 525:1 - 27, xiii; http://dx.doi.org/10.1007/978-1-59745-554-1_1; PMID: 19252861
   PubMedGoogle Scholar
• Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9:767 - 74; http://dx.doi.org/10.1038/nrd3229; PMID: 20811384
   PubMed Web of Science ®Google Scholar
• Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005; 23:1105 - 16; http://dx.doi.org/10.1038/nbt1126; PMID: 16151404
   PubMed Web of Science ®Google Scholar
• Groves MA, Osbourn JK. Applications of ribosome display to antibody drug discovery. Expert Opin Biol Ther 2005; 5:125 - 35; http://dx.doi.org/10.1517/14712598.5.1.125; PMID: 15709915
   PubMed Web of Science ®Google Scholar
• Ladner RC, Sato AK, Gorzelany J, de Souza M. Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov Today 2004; 9:525 - 9; http://dx.doi.org/10.1016/S1359-6446(04)03104-6; PMID: 15183160
   PubMed Web of Science ®Google Scholar
• Brekke OH, Løset GA. New technologies in therapeutic antibody development. Curr Opin Pharmacol 2003; 3:544 - 50; http://dx.doi.org/10.1016/j.coph.2003.05.002; PMID: 14559101
   PubMed Web of Science ®Google Scholar
• Osbourn J, Jermutus L, Duncan A. Current methods for the generation of human antibodies for the treatment of autoimmune diseases. Drug Discov Today 2003; 8:845 - 51; http://dx.doi.org/10.1016/S1359-6446(03)02803-4; PMID: 12963321
   PubMed Web of Science ®Google Scholar
• Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 1997; 15:553 - 7; http://dx.doi.org/10.1038/nbt0697-553; PMID: 9181578
   PubMed Web of Science ®Google Scholar
• Shibasaki S, Ueda M. Development of yeast molecular display systems focused on therapeutic proteins, enzymes, and foods: functional analysis of proteins and its application to bioconversion. Recent Pat Biotechnol 2010; 4:198 - 213; http://dx.doi.org/10.2174/187220810793611545; PMID: 21171957
   PubMedGoogle Scholar
• Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol 2007; 5:518 - 28; http://dx.doi.org/10.1038/nrmicro1690; PMID: 17558424
   PubMed Web of Science ®Google Scholar
• Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 2010; 6:e1000823; http://dx.doi.org/10.1371/journal.ppat.1000823; PMID: 20369024
   PubMed Web of Science ®Google Scholar
• Guzman MG, Hermida L, Bernardo L, Ramirez R, Guillén G. Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines 2010; 9:137 - 47; http://dx.doi.org/10.1586/erv.09.139; PMID: 20109025
   PubMed Web of Science ®Google Scholar
• Gromowski GD, Barrett ND, Barrett AD. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 2008; 82:8828 - 37; http://dx.doi.org/10.1128/JVI.00606-08; PMID: 18562544
   PubMed Web of Science ®Google Scholar
• Rajamanonmani R, Nkenfou C, Clancy P, Yau YH, Shochat SG, Sukupolvi-Petty S, et al. On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J Gen Virol 2009; 90:799 - 809; http://dx.doi.org/10.1099/vir.0.006874-0; PMID: 19264660
   PubMed Web of Science ®Google Scholar
• Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 2010; 84:9227 - 39; http://dx.doi.org/10.1128/JVI.01087-10; PMID: 20592088
   PubMed Web of Science ®Google Scholar
• Zhu Z, Dimitrov DS. Construction of a large naïve human phage-displayed Fab library through one-step cloning. [xv.] Methods Mol Biol 2009; 525:129 - 42, xv; http://dx.doi.org/10.1007/978-1-59745-554-1_6; PMID: 19252833
   PubMedGoogle Scholar
• Chen W, Zhu Z, Liao H, Quinnan GV Jr., Broder CC, Haynes BF, et al. Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins. Viruses 2010; 2:547 - 65; http://dx.doi.org/10.3390/v2020547; PMID: 21755021
   PubMed Web of Science ®Google Scholar
• Giudicelli V, Brochet X, Lefranc MP. IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harb Protoc; 2011:695-715.
   Google Scholar
• Zhang MY, Choudhry V, Sidorov IA, Tenev V, Vu BK, Choudhary A, et al. Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J Immunol Methods 2006; 317:21 - 30; http://dx.doi.org/10.1016/j.jim.2006.09.016; PMID: 17078964
   PubMed Web of Science ®Google Scholar
• Glanville J, Zhai W, Berka J, Telman D, Huerta G, Mehta GR, et al. Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc Natl Acad Sci U S A 2009; 106:20216 - 21; http://dx.doi.org/10.1073/pnas.0909775106; PMID: 19875695
   PubMed Web of Science ®Google Scholar
• Arnaout R, Lee W, Cahill P, Honan T, Sparrow T, Weiand M, et al. High-resolution description of antibody heavy-chain repertoires in humans. PLoS One 2011; 6:e22365; http://dx.doi.org/10.1371/journal.pone.0022365; PMID: 21829618
   PubMedGoogle Scholar
• Kita Y, Tseng J, Horan T, Wen J, Philo J, Chang D, et al. ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies. Biochem Biophys Res Commun 1996; 226:59 - 69; http://dx.doi.org/10.1006/bbrc.1996.1311; PMID: 8806592
   PubMed Web of Science ®Google Scholar
• Yip YL, Smith G, Koch J, Dübel S, Ward RL. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. J Immunol 2001; 166:5271 - 8; PMID: 11290813
   PubMed Web of Science ®Google Scholar
• Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 2011; 25:13 - 25; http://dx.doi.org/10.2165/11539590-000000000-00000; PMID: 21090841
   PubMed Web of Science ®Google Scholar
• Bornstein GG, Quéva C, Tabrizi M, van Abbema A, Chavez C, Wang P, et al. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Invest New Drugs 2010; 28:561 - 74; http://dx.doi.org/10.1007/s10637-009-9291-z; PMID: 19626278
   PubMed Web of Science ®Google Scholar
• Reichert JM. Next Generation and Biosimilar Monoclonal Antibodies: Essential Considerations Towards Regulatory Acceptance in Europe; February 3-4, 2011; Freiburg, Germany. MAbs; 3.
   Google Scholar
• Ledford H. ‘Biosimilar’ drugs poised to penetrate market. Nature 2010; 468:18 - 9; http://dx.doi.org/10.1038/468018a; PMID: 21048737
   PubMed Web of Science ®Google Scholar
• Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 2008; 15:312 - 7; http://dx.doi.org/10.1038/nsmb.1382; PMID: 18264114
   PubMed Web of Science ®Google Scholar